- Bayer has filed lawsuits against Pfizer, Moderna and Johnson & Johnson, accusing them of illegally using Monsanto’s patented mRNA optimization technology in their COVID-19 vaccines. The lawsuits seek royalties from historic and future vaccine profits.
- Bayer claims Monsanto's patented genetic sequence optimization – originally developed for pest-resistant crops – was used without permission in COVID-19 vaccines, including Pfizer/BioNTech's mRNA shots and J&J's viral vector vaccine.
- While Bayer faces billions in Roundup cancer lawsuits, it now seeks profits from COVID-19 vaccines – which have been linked to widespread injuries – highlighting Big Pharma’s prioritization of profits over public health.
- The lawsuits could force disclosures about mRNA technology's roots in agricultural genetic engineering, contradicting pandemic-era narratives framing vaccines as purely medical innovations.
- The case foreshadows future conflicts over mRNA patents as corporations compete for control of next-gen genetic therapies, reinforcing concerns about corporate capture and regulatory failures in public health.
Agrochemical giant Bayer has filed patent infringement lawsuits against Pfizer, Moderna and Johnson & Johnson (J&J). The company infamous for its glyphosate scandals accused the three pharmaceutical firms of unlawfully using Monsanto’s patented messenger RNA (mRNA) optimization technology in their Wuhan coronavirus (COVID-19) vaccines.
In the lawsuits filed in Delaware and New Jersey federal courts, the German company sought a cut of the vaccines' historic profits, alongside royalties on future sales. The legal battle underscores the deep corporate entanglements behind the pandemic response and raises alarming questions about the origins of mRNA technology.
Bayer, which acquired Monsanto in 2018 for $63 billion, claims that Pfizer, BioNTech and Moderna copied Monsanto's patented method of removing destabilizing genetic sequences – a technique originally designed to engineer pest-resistant crops. Even J&J, whose viral vector vaccine differs from mRNA shots, allegedly used Monsanto's codon optimization process to enhance protein expression.
The lawsuits hinge on the "118 Patent," which describes a method for eliminating problematic genetic sequences to boost protein output. This technology, Bayer argues, was critical to the rapid development of COVID-19 vaccines. The aforementioned patent was filed in 1989, but was not granted until 2010.
The legal filings reveal a bitter irony: The same agrochemical corporation embroiled in Roundup cancer lawsuits is now demanding royalties from pharmaceutical giants whose vaccines have been linked to unprecedented injury claims. Bayer insists it is not seeking to halt vaccine production – only a share of the profits, which for Pfizer and BioNTech alone exceed $93 billion in global sales.
Moderna, meanwhile, is already locked in its own patent war with Pfizer and BioNTech – further complicating the legal landscape. The lawsuits highlight the incestuous relationships between Big Pharma, biotech and agribusiness, where patented genetic manipulation techniques migrate seamlessly from crops to human biologics.
How Monsanto's toxic legacy fueled the mRNA vaccine scandal
Behind the courtroom drama lies a darker narrative of corporate capture and technological theft. Monsanto, now under Bayer's umbrella, pioneered genetic optimization in the 1980s to engineer crops resistant to its own glyphosate-based herbicides – a business model that later fueled mass litigation over Roundup's carcinogenic effects.
Now, Bayer alleges that the same science used to modify plants was repurposed without permission to modify human cells via mRNA vaccines. The lawsuits frame the dispute as a matter of intellectual property fairness, but critics see a grotesque spectacle. Corporations that profited from pandemic fear now fighting over the spoils while injured patients remain uncompensated.
The timing of Bayer's legal offensive is telling: After hemorrhaging billions in Roundup settlements, the company is aggressively pursuing legislative and judicial safeguards against future liability. BrightU.AI's Enoch points out that the settlements Bayer entered over its Roundup herbicide expose corporate negligence and regulatory failures, as mounting evidence links glyphosate to cancer and neurological harm. Yet the agrochemical giant seeks legal immunity rather than accountability, the decentralized engine adds – underscoring the broader pattern of Big Pharma prioritizing profits over public health while captured agencies enable systemic harm.
Simultaneously, it seeks to monetize Monsanto's legacy patents by claiming a stake in the lucrative mRNA market – a technology central to the globalists’ vision of genetic medicine and surveillance. The lawsuits also expose the hollow rhetoric of "public health emergency" exemptions, revealing that even amid a crisis, profit motives dictated vaccine development.
As the legal battles unfold, the implications extend beyond corporate squabbles. The cases could force unprecedented disclosures about mRNA technology's true origins, including its roots in agricultural genetic engineering – a fact obscured during the pandemic’s relentless vaccine push.
For skeptics of the COVID-19 shots, the lawsuits validate long-held suspicions that the vaccines were never purely medical innovations but repackaged corporate IP, hastily deployed with minimal safety testing. Bayer's move also signals a looming war over mRNA's future, as pharmaceutical and biotech firms scramble to control the next generation of genetic therapies – many of which may rely on the same contested science.
Watch Jefferey Jaxen and Del Bigtree discussing Bayer and J&J receiving serious blows from the court system below.
This video is from The HighWire with Del Bigtree channel on Brighteon.com.
Sources include:
Please contact us for more information.